Global Obesity Drugs Sales Could Top $44 Billion in 2030, says Bloomberg Intelligence Sales of branded anti-obesity drugs (AOB) could hit $44 billion (risk adjusted) in 2030 vs. $2.5 billion in 2022, with just under 70% stemming from the US, finds Bloomberg Intelligence (BI). Analysts believe securing broad rei.